Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder - Trial 2020-003972-42
Access comprehensive clinical trial information for 2020-003972-42 through Pure Global AI's free database. This phase not specified trial is sponsored by Pfizer, Inc. and is currently status unknown. The study focuses on Bipolar Disorder.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2020-003972-42
Trial Details
EU Clinical Trials Register • 2020-003972-42
Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder
Study Focus
Sponsor & Location
Pfizer, Inc.
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
Imminent risk of suicide or homicide, as judged by the site investigator; any history of serious or unstable medical illness, including risk for QT prolongation.
ICD-10 Classifications
Bipolar affective disorder
Other bipolar affective disorders
Bipolar affective disorder, unspecified
Bipolar affective disorder, currently in remission
Bipolar affective disorder, current episode mixed
Data Source
EU Clinical Trials Register
2020-003972-42
Non-Device Trial